The future of antibodies as cancer drugs

Drug Discovery Today
Janice M Reichert, Eugen Dhimolea

Abstract

Targeted therapeutics such as monoclonal antibodies (mAbs) have proven successful as cancer drugs. To profile products that could be marketed in the future, we examined the current commercial clinical pipeline of mAb candidates for cancer. Our analysis revealed trends toward development of a variety of noncanonical mAbs, including antibody-drug conjugates (ADCs), bispecific antibodies, engineered antibodies and antibody fragments and/or domains. We found substantial diversity in the antibody sequence source, isotype, carbohydrate residues, targets and mechanisms of action (MOA). Although well-validated targets, such as epidermal growth factor receptor (EGFR) and CD20, continue to provide opportunities for companies, we found notable trends toward targeting less-well-validated antigens and exploration of innovative MOA such as the generation of anticancer immune responses or recruitment of cytotoxic T cells.

References

Apr 20, 2004·Cancer Cell·Matthew C FranklinMark X Sliwkowski
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tania CrombetAgustín Lage
Oct 27, 2005·The Oncologist·David G P Allan
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Andrew M ScottLloyd J Old
May 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Raanan BergerArnon Nagler
Jan 23, 2009·Immunobiology·Cornelia HaasPatrick A Baeuerle
Apr 9, 2009·Nature Biotechnology·Aaron L Nelson, Janice M Reichert
Jun 1, 2008·Biologics : Targets & Therapy·George P Kim, Axel Grothey
Jan 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jennifer L SpratlinS Gail Eckhardt
Jan 19, 2010·Nature Biotechnology·Jonathan ZalevskyJohn R Desjarlais
Jan 23, 2010·MAbs·Aaron L Nelson
Mar 2, 2010·MAbs·Rolf LinkeDiane Seimetz
Mar 5, 2010·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Dafne Müller, Roland E Kontermann
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerSuzanne L Topalian
Nov 3, 2010·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Etsuji Kaneko, Rinpei Niwa
Nov 16, 2010·Seminars in Oncology·Antoni Ribas
Jan 11, 2011·Cellular & Molecular Immunology·Dass S Vinay, Byoung S Kwon
Apr 5, 2011·Experimental Cell Research·John R Desjarlais, Greg A Lazar
May 4, 2011·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Niklaus G SchaeferRichard L Wahl
May 24, 2011·Expert Opinion on Investigational Drugs·Puja SapraHans-Peter Gerber
Jun 18, 2011·Expert Opinion on Biological Therapy·Rodrigo Dienstmann, Enriqueta Felip
Oct 18, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Beverly A Teicher, Ravi V J Chari
Oct 18, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alejandro D Ricart
Oct 28, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Zahra HanaiziFrancesco Pignatti
Nov 24, 2011·Current Hematologic Malignancy Reports·Joseph G Jurcic

❮ Previous
Next ❯

Citations

Mar 16, 2013·Proceedings of the National Academy of Sciences of the United States of America·Nicole M OkeleyPeter D Senter
Jun 1, 2013·Science·Kipp WeiskopfK Christopher Garcia
Nov 13, 2012·Journal of Hematology & Oncology·Michael A Firer, Gary Gellerman
Jun 12, 2013·Expert Opinion on Drug Delivery·Ann-Marie ChackoVladimir Muzykantov
Dec 3, 2013·FEBS Letters·Achim DoernerHarald Kolmar
Jul 23, 2013·Critical Reviews in Oncology/hematology·Raphaelle FanciullinoGérard Milano
Sep 30, 2015·Proceedings of the National Academy of Sciences of the United States of America·Andreas LoosLukas Mach
Jul 3, 2015·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Ryutaro Asano, Izumi Kumagai
Dec 20, 2014·MAbs·Karin TaylorStephen M Mahler
Mar 27, 2016·Gynecologic Oncology·Dmitriy Zamarin, Amir A Jazaeri
Jun 13, 2015·Future Medicinal Chemistry·Christopher L AhlbachR Scott Lokey
Dec 18, 2014·Journal of the American Chemical Society·William M HewittR Scott Lokey
Mar 3, 2015·Drug Discovery Today·Roland E Kontermann, Ulrich Brinkmann
Mar 12, 2015·Drug Discovery Today·Natalia Nuñez-PradoLuis Álvarez-Vallina
Jan 16, 2014·MAbs·Debra H JosephsSophia N Karagiannis
Jul 23, 2013·Methods : a Companion to Methods in Enzymology·Brian D HarmsAlexey A Lugovskoy
Aug 15, 2013·Drug Discovery Today·Sven KronenbergThomas Singer
Jan 17, 2015·European Journal of Medicinal Chemistry·Natia Tsomaia
Apr 24, 2014·Regulatory Toxicology and Pharmacology : RTP·Andreas BaumannMarque Todd
Feb 18, 2015·Frontiers in Immunology·Maria VelaLeonor Kremer
May 14, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·Renaud RespaudNathalie Heuzé-Vourc'h
Jul 2, 2016·Journal of Chemical Information and Modeling·Traian SuleaEnrico O Purisima
Jun 3, 2017·Expert Opinion on Drug Metabolism & Toxicology·Milos DokmanovicWen Jin Wu
Jun 13, 2017·International Journal of Molecular Sciences·Mauro CataldiDomenico Capone
Jan 8, 2016·Molecular BioSystems·Louis PapageorgiouDimitrios Vlachakis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.